Healthtech & Medtech, with structure-aware discipline

Regulatory clearance is a value gate. 510(k), De Novo, PMA, CE mark and equivalent clearances gate market entry. Timeline and probability need to be tracked structurally.

Reimbursement drives adoption. CPT codes, DRG assignments and payer coverage determine commercial viability. Reimbursement pathway modelling is core underwriting.

Clinical evidence supports both. Regulatory and reimbursement decisions rest on clinical evidence. Study design, endpoints and evidence generation need tracking.

Health system adoption is slow. Provider adoption cycles are multi-year. Portfolio management workflows need to persist across long adoption timelines.

Healthtech & Medtech carries 7 sub-asset overlays in the Reuben AI rubric registry: Care delivery, Payer and claims technology, Clinical software, Remote monitoring, Digital therapeutics, Health data and interoperability and Behavioural health. Those overlays are part of the 314 sub-asset overlays the platform maintains across 56 of its 68 native asset classes.

An overlay never reweights the parent rubric. It adds the extra scoring criteria, risk flags, document types and key term fields that only apply to that slice, so a care delivery deal and a behavioural health deal are both scored on the shared healthtech & Medtech rubric while each is still asked the questions specific to its structure. That is what keeps deals inside one asset class comparable to each other and to the rest of the portfolio.

Selecting an overlay at intake changes what the platform expects: the document checklist, the extraction schema for key terms, and the flags raised when a term sits outside the range the rest of your healthtech & Medtech book has accepted. Nothing is retrofitted later by hand.

Every healthtech & Medtech opportunity that moves through Reuben AI leaves a structured record rather than a folder of documents and a memo. The rubric score is stored with the criteria that produced it, each extracted key term is stored with the clause and page it came from, and every flag is stored with the reason it fired and who cleared it.

The practical effect is that the investment committee paper, the LP report line and the audit trail are all reading the same underlying record. When an LP asks in year three why a healthtech & Medtech position was underwritten the way it was, the answer is retrieved, not reconstructed.

Healthtech & Medtech sits as a core allocation for VC and Growth Equity mandates, and is adjacent or opportunistic for 6 of the other fund types the platform serves.

That matters operationally because most funds do not hold healthtech & Medtech alone. The moment a portfolio spans more than one asset class, comparability becomes the constraint: a position scored on a bespoke healthtech & Medtech spreadsheet cannot be ranked against a position scored somewhere else. Running healthtech & Medtech on the same rubric engine as the rest of the book removes that break.

Reporting inherits the same property. Portfolio monitoring, valuation cadence, capital account movement and LP reporting all draw from the single stored record, so a healthtech & Medtech position appears in the quarterly pack on the same basis as every other holding, with the same evidence behind it.